Related Experiment Video

Updated: Jul 1, 2025

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
07:35

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

2.0K

Research Progress in the Relationship Between Trimethylamine Oxide and Coronary Heart Disease

Honghui Kong, Jinming Cen, Xili Yang

    Alternative Therapies in Health and Medicine
    |March 2, 2024
    PubMed
    Abstract

    Insights

    Trimethylamine N-oxide (TMAO), an intestinal metabolite, contributes to coronary heart disease by damaging blood vessels and promoting clots. Lifestyle changes can reduce TMAO levels, offering a new avenue for prevention and treatment.

    Area of Science:

    • Cardiovascular Research
    • Microbiome Research
    • Metabolic Syndrome

    Background:

    • Coronary heart disease (CHD) is a leading cause of mortality worldwide.
    • Intestinal microbiota metabolites play a significant role in cardiovascular health.
    • Trimethylamine N-oxide (TMAO) has emerged as a key metabolite linked to CHD development.

    Purpose of the Study:

    • To elucidate the mechanisms by which TMAO contributes to coronary heart disease.
    • To explore the potential of targeting TMAO generation and metabolism for therapeutic interventions.
    • To evaluate the clinical utility of TMAO as a predictive biomarker for cardiovascular disease.

    Main Methods:

    • Review and synthesis of existing research on TMAO's role in CHD.
    • Analysis of TMAO's impact on endothelial function, foam cell formation, and thrombosis.
    • Investigation of dietary and lifestyle factors influencing TMAO production.

    Main Results:

    • TMAO promotes CHD by inducing endothelial dysfunction, foam cell formation, and platelet activation.
    • TMAO influences cholesterol and bile acid metabolism, exacerbating cardiovascular risk.
    • Dietary modifications and physical exercise can reduce TMAO levels, mitigating CHD risk.

    Conclusions:

    • TMAO is a significant driver of coronary heart disease through multiple pathogenic pathways.
    • Interventions targeting TMAO production, such as lifestyle changes, hold therapeutic potential.
    • TMAO serves as a valuable biomarker for CHD risk stratification and prognosis assessment.

    More Related Videos

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

    Published on: August 18, 2016

    15.7K
    Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction08:35

    Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

    Published on: August 17, 2022

    2.4K

    Related Concept Videos

    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
    1.3K
    2° Amines to N-Nitrosamines: Reaction with NaNO201:20

    2° Amines to N-Nitrosamines: Reaction with NaNO2

    Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
    4.2K
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
    586
    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    91
    Preparation of Amines: Reduction of Oximes and Nitro Compounds01:29

    Preparation of Amines: Reduction of Oximes and Nitro Compounds

    Oximes can be reduced to primary amines using catalytic hydrogenation, hydride reduction, or sodium metal reduction. The reduction of aliphatic and aromatic nitro compounds to primary amines takes place by either catalytic hydrogenation or by using active metals like Fe, Zn, and Sn in the presence of an acid.
    Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
    3.6K
    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
    1.4K